Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Sitagliptin
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Apo-Sitagliptin · DIN 02428261 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin · DIN 02428261
Manufacturer: Apotex Inc.; listing date 2026-01-30
Health Canada: Marketed since 2025-12-22 · brand APO-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02428261)
Source record
DIN 02428261: Apo-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id APX
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02428261
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91274
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02428261
Shortage record checked October 6, 2026
Apo-Sitagliptin Malate · DIN 02508656 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin Malate · DIN 02508656
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 25 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin Malate: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02508656)
Source record
DIN 02508656: Apo-Sitagliptin Malate
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id APX
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508656
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99800
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: active shortage (reported October 14, 2025, last updated January 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508656
Shortage record checked October 6, 2026
Auro-Sitagliptin · DIN 02529866 · 25 mg · tablet
General benefitMarketed · checked November 16, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Sitagliptin · DIN 02529866
Manufacturer: Auro Pharma Inc.; listing date 2023-03-31
Health Canada: Marketed since 2023-01-05 · brand AURO-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529866)
Source record
DIN 02529866: Auro-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id AUR
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529866
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101909
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: resolved shortage (ended January 30, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529866
Shortage record checked October 6, 2026
Jamp Sitagliptin · DIN 02534134 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Sitagliptin · DIN 02534134
Manufacturer: Jamp Pharma Corporation; listing date 2023-03-31
Health Canada: Marketed since 2023-02-02 · brand JAMP SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02534134)
Source record
DIN 02534134: Jamp Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id JPC
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534134
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102308
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: resolved shortage (ended March 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534134
Shortage record checked October 6, 2026
Januvia · DIN 02388839 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Januvia · DIN 02388839
Manufacturer: Merck Frosst Canada Ltd.; listing date 2013-09-27
Health Canada: Marketed since 2012-09-17 · brand JANUVIA · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388839)
Source record
DIN 02388839: Januvia
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id MFC
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $3.4098; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388839
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87438
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388839
Shortage record checked October 6, 2026
M-Sitagliptin · DIN 02534983 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Sitagliptin · DIN 02534983
Manufacturer: Mantra Pharma Inc.; listing date 2026-07-31
Health Canada: Marketed since 2026-05-11 · brand M-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02534983)
Source record
DIN 02534983: M-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id MAT
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534983
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102387
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534983
Shortage record checked October 6, 2026
Mint-Sitagliptin · DIN 02553910 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Sitagliptin · DIN 02553910
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2026-03-31
Health Canada: Marketed since 2025-12-10 · brand MINT-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02553910)
Source record
DIN 02553910: Mint-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id MIN
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02553910
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104281
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553910
Shortage record checked October 6, 2026
NAT-Sitagliptin · DIN 02558157 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NAT-Sitagliptin · DIN 02558157
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2026-02-27
Health Canada: Marketed since 2026-01-06 · brand NAT-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Natco pharma (canada) inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNAT-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02558157)
Source record
DIN 02558157: NAT-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id NAT
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02558157
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106144
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02558157
Shortage record checked October 6, 2026
PMS-Sitagliptin · DIN 02503840 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Sitagliptin · DIN 02503840
Manufacturer: Pharmascience Inc.; listing date 2025-01-31
Health Canada: Marketed since 2024-11-26 · brand PMS-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02503840)
Source record
DIN 02503840: PMS-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id PMS
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02503840
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99328
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02503840
Shortage record checked October 6, 2026
PRZ-Sitagliptin · DIN 02545837 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PRZ-Sitagliptin · DIN 02545837
Manufacturer: Pharmaris Canada Inc.; listing date 2026-05-29
Health Canada: Marketed since 2026-02-10 · brand PRZ-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Pharmaris canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPRZ-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02545837)
Source record
DIN 02545837: PRZ-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id PRZ
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02545837
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103457
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02545837
Shortage record checked October 6, 2026
Sandoz Sitagliptin · DIN 02504049 · 25 mg · tablet
General benefitMarketed · checked November 17, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Sitagliptin · DIN 02504049
Manufacturer: Sandoz Canada Inc.; listing date 2023-03-31
Health Canada: Marketed since 2023-01-05 · brand SANDOZ SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02504049)
Source record
DIN 02504049: Sandoz Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id SDZ
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02504049
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99350
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504049
Shortage record checked October 6, 2026
Sitagliptin · DIN 02529033 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sitagliptin · DIN 02529033
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-04-28
Health Canada: Marketed since 2023-01-26 · brand SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529033)
Source record
DIN 02529033: Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id SIV
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529033
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101823
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529033
Shortage record checked October 6, 2026
Sitagliptin · DIN 02548550 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sitagliptin · DIN 02548550
Manufacturer: Sanis Health Inc.; listing date 2025-02-28
Health Canada: Marketed since 2024-12-17 · brand SITAGLIPTIN · ATC not recorded · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 25 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02548550)
Source record
DIN 02548550: Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id SAI
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02548550
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103741
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02548550
Shortage record checked October 6, 2026
Taro-Sitagliptin Fumarate · DIN 02531631 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Sitagliptin Fumarate · DIN 02531631
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2023-03-31
Health Canada: Marketed since 2023-01-05 · brand TARO-SITAGLIPTIN FUMARATE · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN FUMARATE) 25 MG · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTaro-Sitagliptin Fumarate: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531631)
Source record
DIN 02531631: Taro-Sitagliptin Fumarate
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id TAR
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531631
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102075
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Teva-Sitagliptin Malate · DIN 02522705 · $0.8197
Shortage status: active shortage (reported June 1, 2026, estimated to end October 16, 2026, last updated October 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531631
Shortage record checked October 6, 2026
Teva-Sitagliptin Malate · DIN 02522705 · 25 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Sitagliptin Malate · DIN 02522705
Manufacturer: Teva Canada Limited; listing date 2024-03-28
Health Canada: Marketed since 2023-08-31 · brand TEVA-SITAGLIPTIN MALATE · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Sitagliptin Malate: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02522705)
Source record
DIN 02522705: Teva-Sitagliptin Malate
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002046; group id 756; item number 1854; lccId None; manufacturer id TEV
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02522705
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101181
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512475 · $0.8197
Apo-Sitagliptin · DIN 02428261 · $0.8197
Apo-Sitagliptin Malate · DIN 02508656 · $0.8197
Auro-Sitagliptin · DIN 02529866 · $0.8197
Jamp Sitagliptin · DIN 02534134 · $0.8197
Januvia · DIN 02388839 · $0.8197
M-Sitagliptin · DIN 02534983 · $0.8197
Mint-Sitagliptin · DIN 02553910 · $0.8197
NAT-Sitagliptin · DIN 02558157 · $0.8197
PMS-Sitagliptin · DIN 02503840 · $0.8197
PRZ-Sitagliptin · DIN 02545837 · $0.8197
Sandoz Sitagliptin · DIN 02504049 · $0.8197
Sitagliptin · DIN 02529033 · $0.8197
Sitagliptin · DIN 02548550 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531631 · $0.8197
Shortage status: active shortage (reported March 5, 2025, last updated December 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02522705
Shortage record checked October 6, 2026
Apo-Sitagliptin · DIN 02428288 · 50 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin · DIN 02428288
Manufacturer: Apotex Inc.; listing date 2026-01-30
Health Canada: Marketed since 2025-12-22 · brand APO-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02428288)
Source record
DIN 02428288: Apo-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02428288
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91275
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
Januvia · DIN 02388847 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02428288
Shortage record checked October 6, 2026
Apo-Sitagliptin Malate · DIN 02508664 · 50 mg · tablet
General benefitMarketed · checked November 16, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin Malate · DIN 02508664
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin Malate: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02508664)
Source record
DIN 02508664: Apo-Sitagliptin Malate
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508664
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99801
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
Januvia · DIN 02388847 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: active shortage (reported November 4, 2025, last updated January 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508664
Shortage record checked October 6, 2026
Auro-Sitagliptin · DIN 02529874 · 50 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Sitagliptin · DIN 02529874
Manufacturer: Auro Pharma Inc.; listing date 2023-03-31
Health Canada: Marketed since 2023-01-05 · brand AURO-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529874)
Source record
DIN 02529874: Auro-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id AUR
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529874
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101910
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
Januvia · DIN 02388847 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: resolved shortage (ended January 30, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529874
Shortage record checked October 6, 2026
Jamp Sitagliptin · DIN 02534142 · 50 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Sitagliptin · DIN 02534142
Manufacturer: Jamp Pharma Corporation; listing date 2023-03-31
Health Canada: Marketed since 2023-02-02 · brand JAMP SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02534142)
Source record
DIN 02534142: Jamp Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id JPC
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534142
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102309
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Januvia · DIN 02388847 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534142
Shortage record checked October 6, 2026
Januvia · DIN 02388847 · 50 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Januvia · DIN 02388847
Manufacturer: Merck Frosst Canada Ltd.; listing date 2013-09-27
Health Canada: Marketed since 2012-09-17 · brand JANUVIA · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388847)
Source record
DIN 02388847: Januvia
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id MFC
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $3.4098; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388847
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87439
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388847
Shortage record checked October 6, 2026
M-Sitagliptin · DIN 02534991 · 50 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Sitagliptin · DIN 02534991
Manufacturer: Mantra Pharma Inc.; listing date 2026-07-31
Health Canada: Marketed since 2026-05-11 · brand M-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02534991)
Source record
DIN 02534991: M-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id MAT
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534991
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102388
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
Januvia · DIN 02388847 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534991
Shortage record checked October 6, 2026
Mint-Sitagliptin · DIN 02553929 · 50 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Sitagliptin · DIN 02553929
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2026-03-31
Health Canada: Marketed since 2025-12-10 · brand MINT-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02553929)
Source record
DIN 02553929: Mint-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id MIN
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02553929
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104282
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
Januvia · DIN 02388847 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553929
Shortage record checked October 6, 2026
NAT-Sitagliptin · DIN 02558165 · 50 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NAT-Sitagliptin · DIN 02558165
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2026-02-27
Health Canada: Marketed since 2026-01-06 · brand NAT-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Natco pharma (canada) inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNAT-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02558165)
Source record
DIN 02558165: NAT-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id NAT
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02558165
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106145
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
Januvia · DIN 02388847 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
PMS-Sitagliptin · DIN 02503859 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02558165
Shortage record checked October 6, 2026
PMS-Sitagliptin · DIN 02503859 · 50 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Sitagliptin · DIN 02503859
Manufacturer: Pharmascience Inc.; listing date 2025-01-31
Health Canada: Marketed since 2024-11-26 · brand PMS-SITAGLIPTIN · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Sitagliptin: Formulary list price $0.82 per unit (the source does not state the unit; exact figure $0.8197). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02503859)
Source record
DIN 02503859: PMS-Sitagliptin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002047; group id 756; item number 1855; lccId None; manufacturer id PMS
Source form: Tab; strength: 50mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8197; ministry $0.8197
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02503859
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99329
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512483 · $0.8197
Apo-Sitagliptin · DIN 02428288 · $0.8197
Apo-Sitagliptin Malate · DIN 02508664 · $0.8197
Auro-Sitagliptin · DIN 02529874 · $0.8197
Jamp Sitagliptin · DIN 02534142 · $0.8197
Januvia · DIN 02388847 · $0.8197
M-Sitagliptin · DIN 02534991 · $0.8197
Mint-Sitagliptin · DIN 02553929 · $0.8197
NAT-Sitagliptin · DIN 02558165 · $0.8197
PRZ-Sitagliptin · DIN 02545845 · $0.8197
Sandoz Sitagliptin · DIN 02504057 · $0.8197
Sitagliptin · DIN 02529041 · $0.8197
Sitagliptin · DIN 02548569 · $0.8197
Taro-Sitagliptin Fumarate · DIN 02531658 · $0.8197
Teva-Sitagliptin Malate · DIN 02522713 · $0.8197
Shortage status: active shortage (reported July 3, 2025, last updated October 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02503859
Shortage record checked October 6, 2026
Other products in the same Health Canada class (A10B, A10BH): coverage varies; not interchangeable
- Linagliptin (Trajenta): general benefit
- Saxagliptin (Onglyza): general benefit
- Canagliflozin (Invokana): general benefit
- Dapagliflozin (Forxiga): general benefit
- Dapagliflozin + metformin (Xigduo): general benefit
- Empagliflozin (Jardiance): general benefit
11 more in the class list below
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered
Matched class: 68:20:02 Oral Anti-Diabetic Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN
Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL
68:20:02 Oral Anti-Diabetic Agents
· 1 products · General benefit · strengths: 5mg · Tab
· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab
· 8 products · General benefit · strengths: 100mg, 300mg · Tab
· 22 products · General benefit · strengths: 5mg, 10mg · Tab
· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab
· 2 products · General benefit · strengths: 10mg, 25mg · Tab
· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab
· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab
· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab
· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab
· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab
· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02
and 5 more
Full class listing
Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed)
Same formulary class, not same indication: class membership alone does not establish equivalent uses.